No Data
No Data
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
UK Considers GBP129 Million Subsidy for BioNTech to Secure Investment
UK Court Sides With Pfizer, BioNTech in MRNA Patent Case Against CureVac
Express News | Pfizer, BioNTech Win Bid in UK Court to Invalidate CureVac's Patents Over Mrna Technology in Covid-19 Vaccines
HSBC Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $136
BioNTech Is Maintained at Buy by HSBC
No Data
No Data